Haemonetics Corporation HAE R2KR3KPHARMA

Q: What is the current share price of Haemonetics Corporation (HAE)?

As of 2026-09-07 16:24 PDT, Haemonetics Corporation (HAE) trades at $102.92 on NYSE. Its 52-week range is $47.67 to $108.80.

Q: What is the market capitalisation of HAE?

Haemonetics Corporation (HAE) has a market capitalisation of $4.68B on NYSE.

Q: What is the P/E ratio of HAE?

HAE trades at a trailing price-to-earnings (P/E) ratio of 49.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.99.

Q: What is the return on equity (ROE) of HAE?

HAE has a return on equity (ROE) of 11.20%. Its return on capital employed (ROCE) is 7.42%.

Q: Is HAE a good stock to buy?

This page provides a data-driven analysis of Haemonetics Corporation (HAE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.haemonetics.com

Company Profile ↓

$102.92

+91.02% 1Y

Mkt Cap$4.68B

P/E49.72

P/B4.99

52W High$108.80

52W Low$47.67

Book Value$17.60

EPS (TTM)$2.07

Company Overview

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Why Investors Should Care

Healthy Margins

Operating margin of 16.9% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of $1.33B (-2.0% YoY); net profit $97.31M.
Trailing 12 Months Year-on-year growth — revenue +5.6%, earnings +2.9%.
5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR 3.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	4.83%
1 Year:	5.60%

Compounded Profit Growth

5 Years:	2.96%
1 Year:	2.90%

Stock Price Performance

1 Year:	+91.02%
6 Months:	+60.49%
3 Months:	+44.39%
1 Month:	+21.05%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 90% of range

$47.67 $108.80

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)65.29 · Neutral

Price Performance

1M+21.05%

3M+44.39%

6M+60.49%

1Y+91.02%

Valuation vs Sector

P/E of 49.72 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

49.72

Industry PE

25.17

Forward P/E

18.29

PEG Ratio

1.24

Book Value

$17.60

Price to Book

4.99

P/S

2.96

EV/EBITDA

13.78

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

4.83%

Profit 5Y

2.96%

Revenue (YoY)

5.60%

Earnings (YoY)

2.90%

Profitability & Returns

ROCE

7.42%

ROE

11.20%

ROA

6.61%

Profit Margin

7.12%

Op Margin

16.93%

Gross Margin

59.42%

EPS (Latest Qtr)

$0.72

EPS (TTM)

$2.07

Balance Sheet & Liquidity

Debt/Equity

1.40

Quick Ratio

1.67

Current Ratio

3.08

Debt

$1.17B

Total Assets

$2.37B

Current Assets

Working Capital

Ownership

Promoter Holding

1.26%

Chg in Prom Hold

-0.00%

FII / Inst Holding

112.61%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$4.68B

Total Revenue (TTM)

$1.35B

EBITDA

$359.09M

Free Cash Flow

$316.22M

Operating Cash Flow

$328.15M

Shares Outstanding

45.50M

Gross Margin

59.42%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	HAE Haemonetics Corporation R2KR3KPHARMA	102.92	49.72	$4.68B	0.00%	7.42%	11.20%	4.83%	2.96%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Apr 2016	Jul 2016	Oct 2016	Dec 2016	Apr 2017	Jul 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Apr 2021	Jul 2021	Oct 2021	Jan 2022	Jul 2022	Oct 2022	Dec 2022	Jul 2023	Sep 2023	Dec 2023	Jun 2024	Sep 2024	Dec 2024	Jun 2025	Sep 2025	Dec 2025	Jun 2026
Revenue	-	-	-	-	-	-	-	-	210.95M	225.38M	234.04M	-	229.35M	241.58M	247.36M	-	238.45M	252.57M	258.97M	-	195.58M	209.49M	240.37M	-	228.53M	239.90M	259.77M	261.46M	297.49M	305.30M	311.33M	318.18M	336.25M	336.17M	345.51M	348.54M	321.39M	327.31M	338.97M	339.38M
Gross Profit	102.54M	105.30M	108.86M	89.22M	91.06M	104.25M	101.08M	82.11M	91.67M	104.56M	111.30M	104.39M	83.24M	111.91M	111.17M	111.21M	115.91M	127.00M	128.05M	113.56M	90.03M	105.74M	120.26M	81.81M	108.08M	122.54M	138.56M	142.26M	157.88M	158.71M	167.26M	170.51M	177.87M	174.92M	187.44M	193.55M	192.24M	194.74M	202.39M	202.80M
Operating Income	3.61M	19.18M	-61.18M	-5.55M	-7.88M	24.79M	21.21M	-57.51M	16.61M	24.26M	1.01M	14.28M	5.29M	26.08M	28.32M	23.86M	-13.30M	49.74M	40.91M	26.01M	11.71M	58.78M	40.42M	-21.18M	1.39M	24.51M	35.65M	30.77M	46.73M	43.28M	53.66M	35.30M	45.98M	39.76M	51.70M	59.03M	53.87M	58.49M	67.40M	57.46M
Net Income	-267.00K	12.86M	-59.44M	-8.73M	-10.35M	19.82M	15.39M	-51.14M	20.14M	20.10M	-6.55M	11.88M	-2.82M	18.73M	-8.48M	20.84M	-8.48M	37.49M	29.89M	17.62M	10.53M	48.10M	31.88M	-11.04M	-4.45M	14.86M	23.23M	19.88M	33.20M	32.94M	41.04M	24.91M	31.24M	38.37M	33.83M	37.49M	34.03M	38.68M	44.74M	33.01M
Diluted EPS	-0.01	0.25	-1.17	-0.17	-0.20	0.38	0.30	-0.98	0.38	0.38	-0.12	0.22	-0.05	0.35	0.35	0.40	-0.17	0.72	0.58	0.34	0.21	0.94	0.62	-0.22	-0.09	0.29	0.45	0.38	0.64	0.64	0.80	0.48	0.61	0.74	0.66	0.74	0.70	0.81	0.95	0.72
R&D Expense	11.32M	11.55M	10.94M	-	11.44M	8.34M	8.46M	-	8.19M	7.52M	12.43M	-	9.41M	8.58M	8.98M	-	7.49M	7.42M	7.00M	-	7.75M	6.76M	7.50M	-	12.70M	10.85M	10.04M	10.90M	10.90M	12.69M	12.65M	12.66M	13.27M	14.45M	14.14M	15.83M	16.26M	14.87M	14.19M	16.20M

Profit & Loss (Annual)

Figures in USD.

Metric	Mar 2009	Apr 2010	Apr 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Apr 2016	Apr 2017	Mar 2018	Mar 2019	Mar 2020	Apr 2021	Apr 2022	Apr 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	597.88M	645.43M	676.69M	727.84M	891.99M	938.51M	910.37M	908.83M	886.12M	903.92M	967.58M	988.48M	870.46M	993.20M	1.17B	1.31B	1.36B	1.33B
Gross Profit	308.17M	337.48M	355.21M	369.24M	428.13M	468.37M	434.42M	405.91M	378.49M	411.91M	417.54M	484.51M	397.84M	505.50M	615.10M	691.55M	748.96M	787.59M
Operating Income	85.57M	83.28M	110.55M	88.76M	56.44M	46.43M	40.54M	-43.94M	-19.38M	56.16M	83.55M	103.35M	89.75M	80.75M	156.03M	164.88M	221.82M	156.73M
Net Income	59.30M	58.37M	79.98M	66.89M	38.80M	35.15M	16.90M	-55.58M	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.40M	117.56M	167.68M	97.31M
Diluted EPS	2.27	2.24	1.56	1.30	0.74	0.67	0.32	-1.09	-0.51	0.85	1.04	1.48	1.55	0.84	2.24	2.29	3.31	2.05
R&D Expense	23.86M	26.38M	32.66M	36.80M	44.39M	54.20M	54.19M	44.97M	37.56M	39.23M	35.71M	30.88M	32.86M	46.80M	50.13M	54.44M	62.72M	59.77M

Balance Sheet (Annual)

Figures in USD.

Metric	Mar 2008	Mar 2009	Apr 2010	Apr 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Apr 2016	Apr 2017	Mar 2018	Mar 2019	Mar 2020	Apr 2021	Apr 2022	Apr 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	-	764.30M	833.26M	911.13M	1.46B	1.51B	1.49B	1.32B	1.24B	1.24B	1.27B	1.27B	1.82B	1.86B	1.93B	2.20B	2.45B	2.40B
Total Equity	494.19M	539.88M	593.12M	686.14M	732.63M	769.18M	837.89M	826.12M	721.57M	739.61M	752.43M	667.87M	587.11M	731.67M	749.42M	818.00M	959.96M	820.84M	796.32M
Cash & Equivalents	133.55M	156.72M	141.56M	196.71M	228.86M	179.12M	192.47M	160.66M	115.12M	139.56M	180.17M	169.35M	137.31M	192.31M	259.50M	284.47M	178.80M	306.76M	245.44M
Long Term Debt	-	-	4.46M	3.97M	2.88M	456.94M	392.06M	406.37M	364.53M	253.62M	59.42M	322.45M	305.51M	690.59M	559.44M	754.10M	797.56M	921.23M	1.22B
Current Liabilities	-	-	135.05M	108.67M	130.74M	180.14M	216.93M	188.68M	185.55M	211.18M	384.70M	235.76M	274.82M	253.50M	442.27M	251.82M	300.38M	578.11M	282.60M

Cash Flows (Annual)

Figures in USD.

Metric	Mar 2009	Apr 2010	Apr 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Apr 2016	Apr 2017	Mar 2018	Mar 2019	Mar 2020	Apr 2021	Apr 2022	Apr 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	116.36M	130.67M	123.45M	115.32M	85.07M	139.52M	127.18M	121.86M	159.74M	220.35M	159.28M	158.22M	108.81M	172.26M	273.06M	181.75M	181.72M	293.22M
Investing Cash Flow	-60.00M	-132.34M	-51.56M	-52.20M	-596.39M	-105.83M	-121.77M	-104.77M	-73.31M	-63.04M	-116.15M	-57.18M	-425.44M	-86.34M	-143.79M	-322.39M	-161.90M	-179.55M
Financing Cash Flow	-30.74M	-13.97M	-18.08M	-30.47M	461.85M	-20.70M	-33.16M	-62.62M	-60.41M	-120.64M	-50.63M	-131.21M	367.45M	-15.75M	-100.36M	38.16M	108.82M	-178.46M
Capital Expenditure	-56.38M	-56.30M	-46.67M	-53.20M	-62.19M	-73.65M	-122.22M	-102.41M	-76.14M	-74.80M	-118.96M	-48.76M	-37.04M	-96.51M	-191.33M	-38.12M	-39.28M	-32.78M
Free Cash Flow	59.98M	74.36M	76.79M	62.12M	22.89M	65.88M	4.96M	19.46M	83.60M	145.55M	40.32M	109.46M	71.77M	75.75M	81.73M	143.63M	142.45M	260.44M
Share Buybacks	60.00M	40.00M	50.00M	50.00M	50.00M	0	39.03M	60.98M	0	100.00M	160.00M	175.00M	0	0	75.00M	0	225.00M	175.00M

Ratios (Annual)

Figures in %.

Metric	Mar 2009	Apr 2010	Apr 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Apr 2016	Apr 2017	Mar 2018	Mar 2019	Mar 2020	Apr 2021	Apr 2022	Apr 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	51.5%	52.3%	52.5%	50.7%	48.0%	49.9%	47.7%	44.7%	42.7%	45.6%	43.2%	49.0%	45.7%	50.9%	52.6%	52.8%	55.0%	59.0%
Operating Margin %	14.3%	12.9%	16.3%	12.2%	6.3%	4.9%	4.5%	-4.8%	-2.2%	6.2%	8.6%	10.5%	10.3%	8.1%	13.4%	12.6%	16.3%	11.7%
Net Margin %	9.9%	9.0%	11.8%	9.2%	4.3%	3.7%	1.9%	-6.1%	-3.0%	5.0%	5.7%	7.7%	9.1%	4.4%	9.9%	9.0%	12.3%	7.3%
ROE %	11.0%	9.8%	11.7%	9.1%	5.0%	4.2%	2.0%	-7.7%	-3.6%	6.1%	8.2%	13.0%	10.9%	5.8%	14.1%	12.2%	20.4%	12.2%
ROCE %	-	13.2%	15.3%	11.4%	4.4%	3.6%	3.1%	-3.9%	-1.9%	6.6%	8.0%	10.4%	5.7%	5.7%	9.3%	8.7%	11.8%	7.4%

Shareholding Pattern

Insiders

1.26%

Institutions

112.61%

Public Float

114.05%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.99%	5.91M	$614.33M
2	Neuberger Berman Group, LLC	9.19%	4.18M	$434.49M
3	Vanguard Portfolio Management LLC	5.60%	2.55M	$264.72M
4	AQR Capital Management, LLC	4.98%	2.27M	$235.62M
5	Vanguard Capital Management LLC	4.53%	2.06M	$214.11M
6	Ariel Investments, LLC	4.53%	2.06M	$214.26M
7	State Street Corporation	4.00%	1.82M	$189.02M
8	Dimensional Fund Advisors LP	3.48%	1.59M	$164.80M
9	Citadel Advisors Llc	3.32%	1.51M	$156.99M
10	Geode Capital Management, LLC	2.83%	1.29M	$133.82M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HAE

Google News Fri, 04 Sep 2026

Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE5DRWxRV282aG8tUHdkaG1Ec0JyTVF2M3RaRFZUVHM2YTMybjZ6bm9JZTNxaVhKV0lEUThScWFiVU40blVBbTF3?oc=5" target="_blank">Haemonetics Stock Price Forecast. Should You Buy HAE?</a>  <f…

Google News Sat, 15 Aug 2026

Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxORGFlaFdFVlJmd01wNm1uR2dmOWdxUUJjaTNkUEtGTHV1YUpjUzY4MGV1MVBERnVTQTY0VUc4RHhYU0V5SXEzWFlNaVVHa256LXRicHBPbVJadEhEZ1dzdWxudVZvWXd3MkNmZVJ2dGNpQkFHcXJVdnJiYzB6Q014cFB1am85SkhFVzFRQk…

Google News Mon, 31 Aug 2026

Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPYXJMYWJHWmNpVWM1OWNIQ2NnVVZXeWpNMGdJXzNHUUNsaUlJNXd0cENJMXRzUnltaVJoQ2w4UzJLQ2xBN0RINUt6ZUF4SElfa1VfckE3WVR2TExiT1ZRNC1XSkxGZ2tQQXllZmtBVGt2bTJnTWJwbFl6cl9UUnZ1OV9oNjQ1dkNuLXBaOW…

Google News hu, 03 Sep 2026

HAE Maintained by Raymond James -- Price Target Raised to $125 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPRVlMd01yYUM1dmdqV1ktTXFGcVpTU1R1T0tNRmRZTlliVWtBcWRLMU5WcVFyd0lJMUF1emtMZXZKamZ4Y205aUx6U195TllXdC1yeWxNWFk4TlJrOUlIVmxzTDItcnM2R0s3alhsLXBqMjVyV3hFRlBheFI3bk1nWXR2NV9saFd1dHJtRk…

Google News ue, 18 Aug 2026

Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQVGxPZ3IzUHB6aXFvSTVDZDRrVHRCVVgzYjJvN3RBeDRsSnROVlJPcmNaRktRbS1jeUVfa2JfYjVNaml6QXdrRGNMcU1HbG9RRnpHUnd0N25pYzJJeE5ENkMzQVdaRjZPZzVMUlZ4TlkyVjRYZnhVdVRsMzQxVWFydw?oc=5" target="_…

Google News Fri, 29 May 2026

HAE - Haemonetics Corp Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFAwWUF5VFdiNVRTZnBCVVduXzhfeXhLbVpMSUJSeUVlTm55TE9fdWFhRGR2OGx2NUlNVnNkMEFLQUxucTh0?oc=5" target="_blank">HAE - Haemonetics Corp Stock Price and Quote</a>  <font color="#6…

HAE — Frequently Asked Questions

What is the current share price of Haemonetics Corporation (HAE)?

As of 2026-09-07 16:24 PDT, Haemonetics Corporation (HAE) trades at $102.92 on NYSE. Its 52-week range is $47.67 to $108.80.

What is the market capitalisation of HAE?

Haemonetics Corporation (HAE) has a market capitalisation of $4.68B on NYSE.

What is the P/E ratio of HAE?

HAE trades at a trailing price-to-earnings (P/E) ratio of 49.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.99.

What is the return on equity (ROE) of HAE?

HAE has a return on equity (ROE) of 11.20%. Its return on capital employed (ROCE) is 7.42%.

Is HAE a good stock to buy?

This page provides a data-driven analysis of Haemonetics Corporation (HAE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Haemonetics Corporation HAE R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us

Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance - Yahoo Finance

Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings - simplywall.st

HAE Maintained by Raymond James -- Price Target Raised to $125 - GuruFocus

Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets - StocksToTrade

HAE - Haemonetics Corp Stock Price and Quote - Finviz

HAE — Frequently Asked Questions

What is the current share price of Haemonetics Corporation (HAE)?

What is the market capitalisation of HAE?

What is the P/E ratio of HAE?

What is the return on equity (ROE) of HAE?

Is HAE a good stock to buy?

Explore More